October 04, 2022
3 min watch
Save
VIDEO: Faricimab improves visual acuity, reduces central subfield thickness
Issue: November 10, 2022
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this Healio Video Perspective from the AAO meeting, Jennifer I. Lim, MD, discusses the year 1 and year 2 data for faricimab for the treatment of age-related macular degeneration and diabetic macular edema.
According to Lim, treatment with faricimab resulted in improvements in visual acuity and reductions in the central subfield thickness and demonstrated extended durability.
Published by:
Sources/Disclosures
Collapse
Source:
Lim JI. Anti-VEGF/anti-Ang2 year 2 outcomes for diabetic macular edema and neovascular AMD. Presented at: American Academy of Ophthalmology meeting; Sept. 30-Oct. 3, 2022; Chicago.
Disclosures:
Lim reports consulting for Genentech and Regeneron.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.